Skip to main content
. 2018 Dec 14;4:714–723. doi: 10.1016/j.trci.2018.10.011

Table 2.

Inclusion and exclusion criteria for the Age-Well clinical trial

Inclusion criteria Exclusion criteria
  • -

    Age ≥65 years

  • -

    Autonomous

  • -

    Living at home

  • -

    Educational level ≥7 years (from the Preparatory Course—1st grade—included)

  • -

    Registered to the social security system

  • -

    Motivated to effectively participate in the project and signing the informed consent form

  • -

    Performance within the normal range on standardized cognitive tests according to agreed study-specific standards (age, sex and education level when available)

  • -

    Native French speaker

  • -

    Available to attend the intervention for the trial duration (24 months)

  • -

    Retired for at least one year

  • -

    No strong preference or aversion for an intervention group

  • -

    No present or past regular or intensive practice of meditation or comparable practices; the practice is considered as regular and/or intensive if i) it occurs more than one day per week for more than six consecutive months over the last 10 years, and/or in case of more than five consecutive days of intensive practice (internship or retreat) over the past 10 years, and/or of more than 25 days of retreats (cumulatively) within the last 10 years

  • -

    Not speaking fluent English

  • -

    Safety concerns in relation to MR scanning (claustrophobia, ferromagnetic object) or PET scanning (blood sampling to check hepatic and renal functions are performed before the PET scans; known hypersensibility to Amyvid or Glucotep)

  • -

    Presence of a major neurological or psychiatric disorder (including an addiction to alcohol or drugs)

  • -

    History of cerebral disease (vascular, degenerative, physical malformation, tumor, or head trauma with loss of consciousness for more than an hour)

  • -

    Presence of a chronic disease or acute unstable illness (respiratory, cardiovascular, digestive, renal, metabolic, hematologic, endocrine or infectious)

  • -

    Current or recent medication that may interfere with cognitive functioning (psychotropic, antihistaminic with anticholinergic action, anti-Parkinson's, benzodiazepines, steroidal anti-inflammatory long-term treatment, antiepileptic or analgesic drugs), the interfering nature of the different treatments being at the discretion of the investigating doctor

  • -

    Being under legal guardianship or incapacitation

  • -

    Participation in another biomedical research protocol including the injection of radiopharmaceuticals

  • -

    Physical or behavioral inability to perform the follow-up visits as planned in the study protocol